Feeder-Free iPSC Derivation via Synthetic mRNA Reprogramming
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating induced pluripotent stem cells (iPSCs) face challenges such as low efficiency, reliance on viral vectors for reprogramming, need for feeder cells, and potential for cellular immune responses, especially when reprogramming non-human mammalian cells like those from baboons, horses, and dogs.
Innovation Solution
The use of synthetic messenger RNA (mRNA) reprogramming factors, specifically engineered variants like Oct4 fused with MyoD or VP16 transactivation domains, is employed to reprogram somatic cells without viral vectors or feeder cells, optimizing cell density and mRNA dosing to enhance efficiency and reduce cellular immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If viral vectors are used for reprogramming, then reprogramming efficiency is improved, but cellular immune responses are induced and integration into host genome occurs
Solution Approach 1:
The patent extracts the reprogramming function from viral vectors and implements it using synthetic mRNA molecules. The mRNA encodes reprogramming factors (Oct4, Sox2, Klf4, c-Myc) that can be transiently expressed without viral integration, thereby eliminating the harmful immune responses and genomic integration risks while maintaining reprogramming efficiency
Solution Approach 2:
The patent uses synthetic mRNA as an intermediary carrier to deliver reprogramming factors into cells. This mRNA intermediary allows for controlled transient expression of reprogramming proteins without the persistent presence and harmful effects of viral vectors, serving as a safe bridge between genetic information delivery and functional protein expression
2Productivity
If feeder cells are used to support reprogramming, then cell survival and reprogramming efficiency are improved, but complexity of the process increases and risk of xeno-contamination occurs
Solution Approach 1:
The patent removes the feeder cell component from the reprogramming system entirely. By using synthetic mRNA with optimized transfection protocols and culture conditions, the system achieves efficient reprogramming without requiring feeder cells, thereby eliminating process complexity and xeno-contamination risks associated with feeder cell maintenance and handling
Solution Approach 2:
The patent enables the reprogramming system to be self-sufficient without feeder cells. The synthetic mRNA delivers all necessary reprogramming factors directly to target cells, and the optimized culture medium provides all required growth factors and nutrients, allowing the system to function autonomously without external feeder cell support
3Reliability
If daily retransfection is performed for 2 weeks, then reprogramming completeness is achieved, but labor intensity and time requirements increase
Solution Approach 1:
The patent performs preliminary optimization of mRNA design, transfection conditions, and culture parameters before the actual reprogramming experiment. This pre-optimization includes selecting optimal mRNA sequences, transfection reagents, and culture media formulations that enable sustained factor expression and efficient reprogramming in fewer transfections, thereby reducing the overall time and labor required
Solution Approach 2:
The patent achieves continuous expression of reprogramming factors through sustained mRNA translation by using stabilized mRNA designs and optimized culture conditions. This continuous factor expression maintains reprogramming pressure throughout the process without requiring frequent retransfections, reducing the 2-week protocol to a more efficient timeline while ensuring complete reprogramming
4Productivity
If conventional reprogramming factors are used, then basic reprogramming function is achieved, but efficiency is limited and chromatin remodeling is insufficient
Solution Approach 1:
The patent creates composite reprogramming factors by fusing transcription factors (Oct4, Sox2, etc.) with potent transactivation domains from viral proteins (VP16, Rta). These chimeric factors combine the DNA-binding specificity of conventional factors with the enhanced transcriptional activation capability of viral domains, resulting in superior reprogramming efficiency and robust chromatin remodeling
Solution Approach 2:
The patent modifies the functional parameters of reprogramming factors by engineering fusion proteins with altered transcriptional activation properties. The viral transactivation domains (VP16, Rta) possess different activation strengths and chromatin-modifying capabilities compared to conventional factors, and these parameter changes enable more efficient epigenetic reprogramming and higher conversion rates to iPSCs
Data Source
AI summary
The present disclosure relates generally to novel methods and compositions for using engineered reprogramming factor(s) for the creation of induced pluripotent stem cells (iPSCs) through a kinetically controlled process. Specifically, this disclosure relates to establishing combinations of reprogramming factors, including fusions between conventional reprogramming factors with transactivation domains, optimized for reprogramming various types of cells. More specifically, the exemplary methods disclosed herein can be used for creating induced pluripotent stem cells from various mammalian cell types, including human fibroblasts. Exemplary methods of feeder-free derivation of human induced pluripotent stem cells using synthetic messenger RNA are also disclosed.